1.Inhibitory Effects of 6-Gingerol on Cytochrome P450 in Human Liver Microsomes.
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):52-58
No abstract available.
Catechols
;
Cytochrome P-450 Enzyme System
;
Cytochromes
;
Fatty Alcohols
;
Humans
;
Liver
;
Microsomes, Liver
2.Current Status of Clinical Research Coordinator's Employment.
Ihn Sook JEONG ; Sangmin CHOE ; Ji Hong SHON ; Won Ock KIM
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):40-51
BACKGROUND: This study was aimed to investigate the current two years' clinical research coordinators (CRCs) employment and estimate total number of CRCs in Korea. METHODS: The participants were administrative officers or head CRCs in institutions designated by Korea Food & Drug Administration (KFDA). Data on the current status of CRCs' employment was collected with self-administered questionnaires or telephone interview. And total number of CRCs in Korea was estimated based on ratio between the number of the KFDA approved clinical trials and current number of CRCs. RESULTS: The number of CRCs was 1381 at 36 centers in 2009 and 1444 at 37 centers in 2010. About 79 percent of CRCs were employed by investigators. The estimated number of CRCs was from 1677 to 1763 at 135 centers in 2009 and from 1802 to 1890 at 142 centers in 2010 based on number of clinical trials approved by KFDA. Two third of regional clinical trial centers (RCTCs) had written employment policy, and 25 percent of RCTCs employed CRCs in a regular position. All RCTCs had educational programs for CRCs and supported CRCs for training outside. 75 percent of RCTCs provided ID card for CRCs belonging to investigators to access to hospital document. Half of RCTCs had CRC registration system in hospital-wide. CONCLUSION: The number of CRCs in Korea can be easily estimated with the number of KFDA approved clinical trials. Majority of RCTCs still employed CRCs in an irregular position, which should be switched to regular position to reduce the CRCs' unsatisfaction. It is also needed to develop centralized CRC management system for CRCs belonging to investigators.
Calcium Hydroxide
;
Employment
;
Head
;
Humans
;
Interviews as Topic
;
Korea
;
Surveys and Questionnaires
;
Research Personnel
;
Zinc Oxide
3.Bioequivalence Study of Two Orally Disintegrating Risperidone Formulations, Risperdal OD(R) Tablet 1mg and Risperdal Quicklet(R) Tablet 1mg in Healthy Korean Volunteers.
Gaeun KANG ; Jin KIM ; Kyung Yeol BAE ; Hee Young SHIN ; Seong Wook JEONG ; Jin Sang YOON ; Jong Keun KIM
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):31-39
BACKGROUND: Risperidone is one of the atypical antipsychotic drugs that have effectiveness in the management of a range of psychiatric illnesses. Orally disintegrating (OD) formulations of risperidone that rapidly dissolve in the mouth, prior to swallowing without water have been developed to overcome any problems related to swallowing and improve acceptability. The goal of this study was to evaluate the bioequivalence of Risperdal OD(R) tablet 1mg and Quicklet(R) tablet 1mg. METHODS: This randomized, open-label, 2-way crossover trial was conducted in 36 healthy male volunteers that received OD risperidone tablet, either the reference formulation (Risperdal Quicklet(R) tablet 1mg), or the test formulation (Risperdal OD(R) tablet 1mg), each in a single administration. Blood samples were obtained during a 24-hour period after dosing. Plasma was analyzed for risperidone by a validated LC-MS/MS. Adverse events were monitored by safety assessments including clinical interview by clinician. Pharmacokinetics were calculated by noncompartmental analysis and compared between two formulations. RESULTS: A total of 36 male volunteers (mean age, 24.2 years; height 174.5 cm; weight 67.6 kg) completed the study. The ANOVA showed no significant effect of sequence, formulation and period of Ln (AUClast) and Ln (Cmax). The 90% confidence intervals for the mean treatment ratios of the Ln (AUClast) and Ln (Cmax) were Ln 0.96 ~ Ln 1.12, Ln 0.97 ~ Ln 1.16, respectively. No serious adverse events were caused by both formulations. CONCLUSION: In this study, a single administration of Risperdal OD(R) tablet 1mg was bioequivalent to a single administration of Risperdal Quicklet(R) tablet 1mg.
Antipsychotic Agents
;
Deglutition
;
Humans
;
Male
;
Mouth
;
Plasma
;
Risperidone
;
Therapeutic Equivalency
4.Recognition of Clinical Research Coordinators among Non-Nursing Major Students.
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):23-30
BACKGROUND: This study was aimed to investigate recognition of clinical research coordinators (CRCs) among non-nursing major students. METHODS: The participants were 424 undergraduate or graduate students whose majors were related to life science, physical therapy or pharmaceutical engineering in three universities located in Busan. Data were collected with self administrated questionnaire including general characteristics (5 items), and recognition of CRCs (4 items). The collected data were coded and was analyzed using SPSS Version 18.0 for Windows for frequency and percentage, or mean and standard deviation. The Chi-squared test was used to assess the relationship between general characteristics and recognition of CRCs. All statistical tests were performed at the 0.05 level of significance for two-tailed tests. RESULTS: The percent of 'ever having heard of CRCs' was 28.3 % and 35.0 % of them showed the intention to work as CRCs. The 'ever having heard of CRCs' was related to major (p<0.001) and 'ever having heard of clinical trials' (p<0.001). The intention to work as CRCs was not related to gender, education, major, and 'ever having heard of clinical trials'. CONCLUSION: The level of 'ever having heard of CRCs' among non-nursing major students was lower than that of nurses. It is needed that more active introduction or promotion of CRCs to non-nursing major students through both regular curriculum or training programs. And it is also recommended to develop the job description for CRCs with nurse license or CRCs without nurse license.
Biological Science Disciplines
;
Calcium Hydroxide
;
Curriculum
;
Humans
;
Intention
;
Job Description
;
Licensure
;
Surveys and Questionnaires
;
Zinc Oxide
5.Reasons for Investigators to Participate Industry Sponsored Clinical Trials.
Joon Hyung KIM ; Won CHOI ; Sung Ho BECK ; Soo Jeong PARK ; Soo Yeon PARK ; Woo Yun SOHN ; Hyun Ho KIM ; Seung Soo KIM ; Hankyu LEE ; Jung Ryun AHN ; Yoon Jung KIM ; Jung Min SEO ; Chung Mo NAM ; Yil Seob LEE
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):14-22
BACKGROUND: It is getting more difficult to involve appropriate investigators in clinical trials. Knowing what investigators want from sponsor initiated clinical trials would help industry cooperate with investigators more efficiently. This study aims to describe the incentives for investigators choosing to participate or not and perform well in sponsored clinical trials. METHODS: Investigators who have participated in GSK sponsored clinical trials were interviewed face-to-face or through e-mail using the standardized questionnaire. Investigators were asked to choose five items and determine the ranking or those five items. RESULTS: Questionnaires answered by 122 investigators were collected. The top three incentives were "Academic merit" (108, 88.5 %), "Expectation of treatment potentially helpful to patient" (101, 82.8 %), and "Access to new treatments" (92, 75.4 %). The disincentives and the factors affecting an investigator's performance were analyzed separately because of the different questionnaire between investigators for medicine and vaccine. Investigators for medicine choose as disincentives "Insufficient time" (43, 61.4 %), "Difficult protocol" (41, 58.6 %), and "Adverse event concerns" (41, 58.6 %). Vaccine investigators pointed out "Limited support staff" (41, 78.8 %), "Insufficient time" (40, 76.9 %), and "Difficult blood sampling" (333, 63.5 %) as disincentives. Factors adversely affecting an investigator's performance showed similar results to those of disincentives. CONCLUSION: Investigators focused on academic curiosity and patients and insufficient time mostly inhibits them from participating and performing clinical trials. Our results would help industry cooperate with investigators more efficiently, finally making companies perform clinical trials more effectively.
Electronic Mail
;
Exploratory Behavior
;
Humans
;
Motivation
;
Surveys and Questionnaires
;
Research Personnel
6.The Suggestions for Improving the Institutional Review Board (IRB) in Clinical Trials: Focusing on Continuing Management.
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2011;19(1):5-13
As Korea has increasing number of clinical trials in recent years, institutional review boards (IRBs) are facing new challenges. The IRB should review submitted documents and supervise clinical trials from the beginning to the end to protect human subjects. Although most IRBs invest much time and efforts to initial review, they rarely conduct proper continuing management at the moment. The purpose of this article is to describe challenges involving continuing management, which includes unanticipated problems, subject's complaints, site visit, and continuing review, and to provide suggestions for improving it. Above all, institutions should perceive the importance of continuing management and they should provide sufficient manpower and resources for the management.
Ethics Committees, Research
;
Ethics, Research
;
Humans
;
Korea
7.A Study on Current Status of Clinical Trial Pharmacy in Domestic Clinical Trial Institution.
Yoo Jeong JANG ; Wonku KANG ; Joomi LEE ; Hae Won LEE ; Min Soo PARK ; Young Ran YOON
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):71-81
BACKGROUND: There is a lack of research on the status of clinical trial pharmacy and clinical trial pharmacist (CTP) in Korea. This study was aimed to investigate the current status of clinical trial pharmacy and clinical trial pharmacists. METHODS: The survey was performed using the 41-item questionnaire designed to investigate information on the following; (1) current status of clinical trial pharmacy designated by Korea Food and Drug Administration, (2) current status of working condition, management, and satisfaction index of CTP. Data collected was analyzed by t-test and chi2. RESULTS: Among the CTPs who responded, 92.7% belonged to department of pharmacy, and 7.3% to clinical trial center. 90.2% of the respondents were women. Forty-two point seven percents of the respondents had more than 3 years of experience in the clinical trial field. 36.6% answered that the current number of CTPs in the institution was '2'. Sixty-three point four percents answered that they subsumed an additional post. Regarding the question on "whether the equipment and working environment of your clinical trials pharmacy is adequate", 65.1% of the respondents answered as 'Inadequate'. Ninety-eight point eight percents answered that work-related education is needed. Ninety-three point nine percents answered that the quality of clinical trials is related to the improvement of the working environment of CTP. CONCLUSION: Clinical trial pharmacy's facility and number of actually working CTP were insufficient. Proper and continuous education and training for CTPs are needed to improve the quality of clinical trials conducted in Korea, with strong institution support and timely regulation change.
Cytidine Triphosphate
;
Surveys and Questionnaires
;
Female
;
Humans
;
Korea
;
Pharmacists
;
Pharmacy
;
Silanes
;
United States Food and Drug Administration
8.A Placebo-Controlled, Single and Multiple Dose Study to Investigate the Appropriate Parameters for Evaluation of Pharmacodynamic Equivalence of Voglibose in Healthy Korean Volunteers.
Kyungho JANG ; Sang Heon CHO ; Jung Ryul KIM ; Jae Yong CHUNG ; Kyoung Soo LIM ; In Jin JANG ; Kyung Sang YU
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):63-70
BACKGROUND: Voglibose is an alpha-glucosidase inhibitor. The purpose of this study was to evaluate the pharmacodynamic characteristics of voglibose for determining the appropriate study design and parameters for a pharmacodynamic equivalence study of voglibose. METHODS: This study consisted of two studies. The single dose study had an open and single sequence design. Nineteen subjects received placebo and then one tablet of voglibose on two consecutive days with sucrose. The multiple dose study was performed with the similar design, except that it was a multiple dose of the single dose study. Nine subjects who showed an effective response in the single dose study received placebo three times and then voglibose 4 times on two consecutive days. Serial blood samples for pharmacodynamic parameters were taken until 180 mins after each administration. The baseline adjusted maximum serum glucose level (G(max)) and area under the serum glucose level-time profiles were determined and compared. RESULTS: In the single dose study, the difference in G(max) was -10.6 +/- 28.7 mg/dL. The area under the serum glucose concentration-time curve (AUGC(0-1h)) of placebo and voglibose were 7825.0 +/- 1145.3 mg.min/dL, 7907.5 +/- 917.2 mg.min/dL, respectively. In the multiple dose study, the difference in G(max) was 46.6 +/- 16.1 mg/dL. The AUGC(0-1h) of placebo and voglibose were 8138.6 +/- 721.9 mg.min/dL and 6499.7 +/- 447.2 mg.min/dL, respectively. The G(max) and AUGC(0-1h) of the multiple dose study was significantly different between placebo and voglibose in paired t-test. CONCLUSION: The differences in G(max) and AUGC(0-1h) are suitable for pharmacodynamic parameters to evaluate bioequivalence of voglibose.
alpha-Glucosidases
;
Glucose
;
Inositol
;
Sucrose
;
Therapeutic Equivalency
9.A Randomized, Placebo Controlled, Double Blind, Parallel Group, Multiple Dosing, Dose Escalation Clinical Study to Evaluate Pharmacokinetics/Pharmacodynamics and Tolerability of Zofenopril in Healthy Korean Subjects.
Jaeseong OH ; Seunghwan LEE ; Kyoung Soo LIM ; Jae Yong CHUNG ; Sang Goo SHIN ; In Jin JANG ; Kyung Sang YU
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):52-62
BACKGROUND: Zofenopril is a new Angiotensin Converting Enzyme (ACE) inhibitor for the treatment of the patients with hypertension and congestive heart failure. This study aimed to evaluate the pharmacokinetics (PKs)/pharmacodynamics (PDs) and tolerability of zofenopril in healthy Korean subjects. METHODS: A randomized, double blind, placebo-controlled, multiple dosing parallel group study with two dosage groups (zofenopril 30 mg or 60 mg) was conducted in healthy Korean male subjects. Each dosage group consisted of 10 subjects and they were randomly assigned to receive zofenopril or placebo with a ratio of 4:1. PK characteristics of zofenopril and its active metabolite, zofenoprilat, were evaluated after single or multiple dosing. Serum ACE activities and blood pressures were measured for PD evaluation. Adverse events, clinical laboratory tests, electrocardiograms, vital signs and physical examinations were performed for tolerability evaluation. RESULTS: The PK characteristics of zofenopril and zofenoprilat after single dose and multiple doses were similar to one another. The metabolic ratio of zofenoprilat to zofenopril after single dose and multiple doses were 12.4 and 14.9, respectively, in the 30 mg dosage group, and were 6.8 and 6.6, respectively, in the 60 mg dosage group. Complete serum ACE activity inhibition was observed within 1 hour in both doses but it was maintained longer in the 60 mg dosage group compared to the 30 mg dosage group. There were no clinically significant abnormalities in tolerability evaluations. CONCLUSION: The PK/PD characteristics of zofenopril and zofenoprilat after single or multiple administrations were explored. Zofenopril was well tolerated after multiple administrations in healthy Korean subjects.
Captopril
;
Electrocardiography
;
Heart Failure
;
Humans
;
Hypertension
;
Male
;
Peptidyl-Dipeptidase A
;
Physical Examination
;
Vital Signs
10.A Randomized, Open Label, 2-Way Crossover Study to Assess the Pharmacokinetic Characteristics and Skin Irritation of Murupe(R) Patch Compared with Trast(R) Patch in Healthy Volunteers.
Yoon Jung CHOI ; Young Mi KIM ; Jae Yong CHUNG ; Joo Youn CHO ; Kyung Sang YU ; In Jin JANG ; Kyoung Soo LIM
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):41-51
BACKGROUND: A piroxicam patch has been widely used to treat musculoskeletal pain. The aim of this study was to assess the pharmacokinetic (PK) characteristics and skin irritation of Murupe(R) patch (piroxicam 96 mg) compared with Trast(R) patch (piroxicam 96 mg) in healthy volunteers. METHODS: A randomized, open-label, 2-way crossover study was conducted in 12 healthy Korean male subjects. They were allocated to one of the two treatment sequences of RT and TR (R, reference drug, Trast(R) patch; T, test drug, Murupe(R) patch). Each patch was applied to the subject once during 48 hours. Serial blood samples were collected up to 72 hours after removing the patch and plasma concentrations were determined by high performance liquid chromatography. Safety was monitored and the skin irritation potential was assessed. RESULTS: The plasma concentration-time profile during 48 hours showed an exponential increase in both of two patch products. Mean C(max) and AUC(last) values were not statistically different between two patch groups. Mean AUC[0-48h] was lower in Murupe(R) patch group than that in Trast(R) patch group; 806.4 and 1196.5 ng.h/mL. However, the mean AUC[48-120h] value tended to be higher in Murupe(R) patch group, implying more delayed excretion than in Trast(R) patch group; 2724.7 ng.h/mL and 1989.2 ng.h/mL. The overall results of skin irritation potential test showed no clinically significant differences between two patch groups. CONCLUSION: Mean Cmax and AUC(last) values in Murupe(R) patch group were comparable to those in Trast(R) patch group. Murupe(R) patch was safe and well tolerated in healthy male subjects.
Chromatography, Liquid
;
Cross-Over Studies
;
Humans
;
Male
;
Musculoskeletal Pain
;
Piroxicam
;
Plasma
;
Skin